Mechanism of Action
MC1R Agonism and Melanogenesis
Afamelanotide binds the melanocortin-1 receptor (MC1R) on melanocytes with higher affinity than endogenous alpha-msh/" class="wiki-internal-link">alpha-MSH. MC1R activation stimulates cAMP production, activating MITF transcription factor, which upregulates tyrosinase and other enzymes in the melanin synthesis pathway. The resulting increase in eumelanin (black/brown pigment) provides photoprotection by absorbing UV radiation and scavenging reactive oxygen species before they damage erythrocyte precursors in EPP patients.
EPP Disease Mechanism
Erythropoietic protoporphyria results from loss-of-function mutations in FECH (ferrochelatase), causing accumulation of protoporphyrin IX in erythrocytes, plasma, and skin. When skin is exposed to UV/visible light (400-420 nm Soret band), protoporphyrin IX undergoes photoexcitation generating singlet oxygen and causing severe burning pain within minutes. Afamelanotide-induced melanin acts as a physical and chemical filter against this specific wavelength range.
Research Summary
FDA Approval for EPP (2019)
FDA ApprovedScenesse (afamelanotide 16 mg implant) was approved by the FDA in October 2019 based on two Phase III placebo-controlled trials demonstrating significant increases in pain-free sun exposure time in EPP patients. Patients receiving afamelanotide spent on average 6 more hours per month in direct sunlight without pain compared to placebo. The drug was previously approved in Europe by EMA in 2014.
Solar Urticaria and Other Uses
Phase IIOff-label and investigational uses include solar urticaria, polymorphous light eruption, and vitiligo. Phase II data for solar urticaria (n=18) showed significant reduction in urticarial reactions and increased UV tolerance. A Phase II trial in vitiligo repigmentation showed modest benefit. None of these indications have received regulatory approval.
Anti-Inflammatory Properties
PreclinicalBeyond pigmentation, MC1R activation exerts anti-inflammatory effects by suppressing NF-kB signaling, reducing pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12), and promoting regulatory T-cell function. These properties have led to investigation in inflammatory skin diseases and multiple sclerosis models, with limited clinical data thus far.
Calculate your Melanotan I dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| EPP (approved use) | 16 mg implant SC | Every 60 days | Subcutaneous implant |
| Solar urticaria (investigational) | 16 mg implant SC | Every 60 days | Subcutaneous implant |
Only the EPP indication is FDA-approved. All other uses are investigational. Must be implanted by a physician.
Interactions
Safety Profile
Afamelanotide is generally well tolerated. The most common adverse events are nausea, fatigue, and site reactions. Hyperpigmentation of moles and freckles occurs and is expected. Unlike Melanotan II, sexual side effects (spontaneous erections) are not a concern due to structural selectivity for MC1R over MC3R/MC4R. No increased melanoma risk has been demonstrated in long-term studies. WADA prohibits use in sport due to potential performance benefits from enhanced photoprotection.
References
- [1]Langendonk JG, et al. (2015). Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med, 373(1), 48-59.
- [2]FDA. (2019). FDA approves afamelanotide for erythropoietic protoporphyria. NDA 210797.
- [3]Minder EI, et al. (2009). Afamelanotide, a synthetic alpha-MSH analogue in the prevention of phototoxic reactions in EPP. J Dermatol Sci, 56(2), 65-70.